Search results for "COMPOUND"
showing 10 items of 35174 documents
Antiketogene Wirkung von Xylit bei alloxandiabetischen Ratten
1963
Bei alloxandiabetischen Ratten mit Ketonurie zeigt Xylit je nach Versuchsbedingungen in 50–80% der Falle eine statistisch gesicherte antiketogene Wirkung.
Limitations of nasal nitric oxide as a screening method of primary ciliary dyskinesia in childhood
2016
Introduction: Nasal nitric oxide (nNO) has been proposed as a screening tool for primary ciliary dyskinesia (PCD). However, there are no reference values by age in consensus guidelines. Objectives: 1) To analyze differences in nNO among a group of patients with PCD and healthy controls. 2) To determine the proportion of pediatric PCD patients with nNO values similar to healthy population. Methods: Determination of nNO by electrochemical system (NIOX Vario®) in patients with DCP (diagnosis confirmed by digital high speed videomicroscopy) and healthy controls (without asthma, rhinitis or atopic dermatitis), aged between 7 and 60 years. Results: 32 patients (17 children, 53.1%) and 32 controls…
Evaluation of early and late histamine release by three standard volume substitutes
2001
Following meta-analysis [1], the use of colloidal solutions in intensive care medicine is under discussion. Although polygeline [2] and human albumin are known to cause histamine release, other substances eg hydroxyethyl starch were thought to be without effect. Histamine release depends on the clinical scenario, concomitant drugs, infusion speed, duration and amount of infusion. However, there is no information about their effect regarding time periods longer than immediate reactions. This study investigated the histamine releasing effects of three plasma substitutes administered and observed over a longer period of time, simulating many of the clinical scenarios.
Phase I/II Study of the Deacetylase Inhibitor Panobinostat As Maintenance Therapy after an Allogeneic Stem Cell Transplantation in Patients with High…
2015
Abstract Background: Leukemic relapse and graft-versus-host disease (GvHD) remain major obstacles after an allogeneic stem cell transplantation (HSCT). Panobinostat is a potent inhibitor of class I, II and IV deacetylases and has shown antileukemic as well as immunomodulatory activity. The hypothesis of our phase I/II PANOBEST trial was that panobinostat can effectively prevent relapse in patients (pts) with high-risk (HR) myeloid diseases while simultaneously reducing GvHD. We aimed to determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of panobinostat in adult pts with HR acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS…
Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myelo…
2018
Abstract Introduction: Mutations localized in the tyrosine kinase domain activation loop of FLT3 (FLT3-TKD), representing point mutations in codon D835/I836 and rarely deletions of codon I836, induce constitutive tyrosine phosphorylation and activation of the receptor tyrosine kinase similarly to FLT3 internal tandem duplication (ITD) mutations. However, the prognostic role of FLT3-TKD in AML, particularly in the presence of NPM1 mutations, is not well established. The phase 3 RATIFY trial [NCT00651261; Stone et al. N Engl J Med. 2017] showed that in combination with standard chemotherapy, midostaurin (PKC412) improved survival outcomes across all 3 FLT3 stratification subgroups (ITD high a…
Seasonal Variations on the Cortisol Concentration of the Subretinal Fluid in Rhegmatogenous Retinal Detachment
1981
Probes of the subretinal fluid were obtained from 115 nonselected retinal detachments, operated on during the period from November 19, 1973 to December 20, 1974. All patients had no known endocrine abnormalities and had not ever received topical or systemic corticosteroid therapy. Subretinal fluid Cortisol was determined by competitive protein binding analysis. A statistically significant increase in mean subretinal fluid Cortisol concentration was found for the winter season (3.3 µg/100 ml), as compared with the summer months (1.5 µg/100 ml). This finding sharply contrasts with the seasonal incidence of the idiopathic retinal detachments which reaches its maximum in the months June to Augu…
Imbalance between the neuromodulatory actions of corticotropin-releasing hormone and corticosterone as a pathophysiologic mechanism in panic disorder
1990
THERAPEUTIC AND COLATERAL EFFECTS OF 25-HYDRXYCHOLECAICI FEROL IN VITAMIN D DEFICIENCY
1974
Vitamin D polar metabolite, 25–HCC has been used in 2 infant groups whose ages range from 0–18 months. In the 1st group of 15 infants, all of them suffered from rickets, clinically, biochemistry and radiologically and no prophylactic vitamin D administration could be demonstrated. The control group (15 infants too) was admitted with similar diseases but no one suffered from rickets. Routine determinations for metabolic assesment of Ca phosphoric metabolism were perforaed in plasma and in 240. urine collections, prior and after 25–HCC adBinietration. The rickets group received 20 mcg/day, orally for 20 days and the control 10mcg/day in the same way. The biochemical study demonstrated that bo…
Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease
2011
The aim of this study was to evaluate micafungin efficacy for treatment of invasive candidiasis/candidaemia in patients with cancer. Modified intent-to-treat populations were analysed from two trials: one, in adults and children with confirmed Candida infection, compared micafungin (adults 100 mg day(-1); children 2 mg kg(-1) day(-1)) with liposomal amphotericin B (L-AmB 3 mg kg(-1) day(-1)); and the other, in adults only, compared micafungin (100 or 150 mg day(-1)) with caspofungin (50 mg day(-1); 70 mg loading dose). Primary efficacy endpoint in both trials was treatment success, defined as both clinical and mycological response at end of therapy. In the micafungin/L-AmB trial, 183/489 pa…